MA-891 Cells
General information
| Description | MA-891 is a highly metastatic murine mammary gland carcinoma cell line, established from a spontaneous mammary tumor in a mouse and selected for its aggressive metastatic behavior. The line grows as an adherent monolayer and is classified as a syngeneic tumor cell line compatible with immunocompetent mouse hosts, enabling in vivo studies of mammary carcinoma growth, metastasis, and immune interaction. MA-891 represents a highly metastatic variant selected for its propensity to disseminate to distant organs, particularly the lungs. MA-891 is applicable in murine mammary carcinoma research including studies of metastatic cascade biology, invasion, angiogenesis, tumor-immune interactions, and preclinical evaluation of anti-metastatic and anti-tumor agents. Its syngeneic origin enables testing of immunotherapy approaches in immunocompetent hosts, including checkpoint inhibitor evaluation and cancer vaccine development. The high metastatic potential makes it a useful model for studying metastasis prevention strategies and the biology of aggressive mammary carcinoma. |
|---|---|
| Organism | Mouse |
| Tissue | Mammary gland |
| Disease | Carcinoma |
| Metastatic site | Metastatic (high metastatic potential; primarily to lungs) |
| Applications | Murine mammary carcinoma research; metastasis biology; anti-metastatic drug evaluation; syngeneic tumor immunotherapy; tumor-immune interaction; cancer vaccine studies |
| Synonyms | Mouse Mammary Carcinoma Highly Metastatic Cell Line |
Characteristics
| Age | Age unspecified |
|---|---|
| Gender | Female |
| Ethnicity | Unspecified |
| Morphology | Epithelial-like |
| Cell type | Tumor Cell Line |
| Growth properties | Adherent |
Regulatory Data
| Citation | MA-891 (Cytion catalog number 305581) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 10090 |
Biomolecular Data
Handling
| Culture Medium | RPMI-1640 with 10% FBS; 1% Penicillin-Streptomycin Solution |
|---|---|
| Supplements | Supplement the medium with 10% FBS and 1% Penicillin-Streptomycin |
| Dissociation Reagent | Accutase |
| Doubling time | approx. 18 to 24 hours |
| Subculturing | Remove medium, wash with PBS without calcium and magnesium, cover with Accutase, incubate 8–10 min at RT, resuspend in medium, centrifuge 300×g 3 min, discard supernatant, reseed in fresh medium. |
| Split ratio | 1 to 5 |
| Seeding density | 1 to 3 × 10⁴ cells/cm² |
| Fluid renewal | Every 2 to 3 days |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |